ArticleNature2024
PGE
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 1 pooled it
40.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.
- Assessing the Carcinogenic Potential of Jet Fuels: A Fit-for-Purpose Systematic Literature Review.Journal of occupational and environmental medicine · 2026Pooled it
- The update of prostaglandin E2 receptor subtype 4 (EP4) in inflammatory diseases.Genes & diseases · 2026Review
- Prostaglandin E2-mediated aging microenvironment fuels pathogenic fibrosis in cesarean section scar defect.EMBO molecular medicine · 2026Article
- Article
- Bioinspired nanoparticles deliver DNase I to attenuate ulcerative colitis by degrading NETs and modulating PTGS2-mediated ER stress.Materials today. Bio · 2026Article
- Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis.Science (New York, N.Y.) · 2026Article
- Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy.Genes & diseases · 2026Review
- An Injectable Metal-Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post-Surgical Osteosarcoma Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer-Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Time-Resolved Metabolomics Reveals Distinct, Cell- and Variety-Dependent Profiles of Prostanoids in Melanoma Cells Exposed to Fruit Extracts fromInternational journal of molecular sciences · 2026Article
- Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer.Bioactive materials · 2026Article
- Review
- Structural and molecular principles of DAMP biology.Nature structural & molecular biology · 2026Review
- Article
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies.Immune network · 2026Review
- TGF-β-producing tBregs are associated with poor survival rates in PTGS2-high cancers.Cell death & disease · 2026Article
- Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer.Signal transduction and targeted therapy · 2026Article
- Persistent prostaglandin E2 upregulation and hormonal multi-resistance: A hypothesis for long COVID.Biochemistry and biophysics reports · 2026Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 5 institutions in 2 countries.
Matteo Morotti *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-1790-1185
Alizee J Grimm *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-4662-5490
Helen Carrasco HopeLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0001-5583-4510
Marion ArnaudLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0003-0534-2379
Mathieu DesbuissonLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Nicolas RayrouxLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
David BarrasLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0001-8985-4704
Maria MasidLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Baptiste MurguesLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Bovannak S ChapLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Marco OngaroLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Ioanna A RotaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Catherine RonetLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0003-1479-2873
Aspram MinasyanLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-0063-2513
Johanna ChiffelleLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-8312-2681
Sebastian B LacherInstitute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Sara BobisseLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Clément MurguesCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Eleonora GhisoniLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Khaoula OuchenLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Ribal Bou MjahedLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Fabrizio BenedettiLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-9959-9142
Naoill AbdellaouiLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Riccardo TurriniLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0003-0133-7492
Philippe O GannonCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Khalil ZamanDepartment of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2997-527X
Patrice MathevetDepartment of Gynaecology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Loic LelievreDepartment of Gynaecology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Isaac CrespoLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Marcus ConradInstitute of Metabolism and Cell Death, Molecular Target and Therapeutics Centre, Helmholtz Munich, Neuherberg, Germany.ORCID 0000-0003-1140-5612
Gregory VerdeilLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Lana E KandalaftCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.ORCID 0000-0002-1575-6674
Julien DagherUnit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.ORCID 0000-0003-3864-5149
Jesus Corria-OsorioLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0001-6844-6170
Marie-Agnes DouceyLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Ping-Chih HoLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0003-3078-3774
Alexandre HarariLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-1055-2090
Nicola VanniniLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-6351-7512
Jan P BöttcherInstitute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.ORCID 0000-0002-8163-8107
Denarda Dangaj LanitiLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland. denarda.dangaj@chuv.ch.ORCID 0000-0002-5659-6427
George CoukosLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland. george.coukos@chuv.ch.ORCID 0000-0001-8813-7367
Ludwig Cancer Research · CHUniversity of Lausanne · CHTechnical University of Munich · DEUniversity Hospital of Lausanne · CHHelmholtz Zentrum München · DE
Funding
University of Lausanne
Abstract
Expansion of antigen-experienced CD8
Indexed as
CD8-Positive T-LymphocytesCell ProliferationDinoprostoneInterleukin-2Lymphocytes, Tumor-InfiltratingMitochondriaSignal TransductionAnimalsDown-RegulationFerroptosisHumansInterleukin-2 Receptor beta SubunitInterleukin Receptor Common gamma SubunitMiceOxidative StressPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaDinoprostoneIL2 protein, humanIL2RB protein, humanIL2RG protein, humanInterleukin-2Interleukin-2 Receptor beta SubunitInterleukin Receptor Common gamma SubunitPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanPTGER2 protein, humanPTGER4 protein, humanReceptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 SubtypeTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.